Difference between revisions of "Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19"

From OmniJournal
Jump to navigation Jump to search
(Created page with "{| class="infobox" width=200px |style="width:100%; font-size:24px;"|'''Publication''' |- |Title || <ul>[https://www.nejm.org/doi/full/10.1056/NEJMoa2019014 Hydroxychloroquine...")
 
Line 19: Line 19:
  
 
A randomized, open-label controlled trial of 504 patients with mild-to-moderate COVID-19 were treated with standard care, hydroxychloroquine or hydroxychloroquine plus azithromycin resulted in no difference in clinical status at 15 days.
 
A randomized, open-label controlled trial of 504 patients with mild-to-moderate COVID-19 were treated with standard care, hydroxychloroquine or hydroxychloroquine plus azithromycin resulted in no difference in clinical status at 15 days.
 +
 +
Of note, the median time between symptoms onset and randomization was reported to be 7 days and included patients up to 14 days after symptom onset.
  
 
== Major Issues ==
 
== Major Issues ==

Revision as of 14:52, 24 July 2020

Publication
Title
Authors
  • Alexandre Cavalcanti
  • Fernando Zampieri
  • Regis Rosa
  • ...
  • Otavio Berwanger
Journal NEJM
Date July 23, 2020

A randomized, open-label controlled trial of 504 patients with mild-to-moderate COVID-19 were treated with standard care, hydroxychloroquine or hydroxychloroquine plus azithromycin resulted in no difference in clinical status at 15 days.

Of note, the median time between symptoms onset and randomization was reported to be 7 days and included patients up to 14 days after symptom onset.

Major Issues

Contribute here!

Minor Issues

Contribute here!

Impact

Contribute here!

Article Revisions

No revisions reported at this time.

References